Prelude Therapeutics priced an underwritten equity offering of 18,018,014 shares of its common stock at $4.44 per share, generating approximately $90 million in gross proceeds. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions.
Continue reading for full analysis...